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Abstract
Oral cancers form one of the most common malignancies seen worldwide, with a
steady increase in number over time. Surgery with the addition of adjuvant therapy
forms the cornerstone of therapeutic management for these cancers. Despite excel-
lent surgical management, loco-regional recurrences have always been of concern.
This has expanded the role of radiotherapy, with concomitant therapies, allowing to
establish an effective management protocol. Over the last two decades, there have
been huge strides taken towards understanding these specific aspects and providing
insight into the most fruitful application of radiotherapy in these patients. In this
chapter, we have presented the oncologists perspective to dealing with the non-
surgical aspects of oral cancer management. We have elaborated on the chronological
order with which radiotherapy has evolved and provided the contemporary aspects
of decision making, essential for current practice. The evidence-based approach will
address all components of radiotherapy workflow from basic understanding of
patient’s anatomy, planning & evaluation during therapy to the outcomes & toxicity
profiles to be expected in day-to-day clinics. Established guidelines have been incor-
porated into the graphical representations to ensure scenario-based understanding.
Future perspectives, essential for identifying the possible direction of therapy &
potential improvements in outcomes, have also been addressed.
Keywords: Oral cancers, Radiotherapy, Adjuvant, Definitive, Brachytherapy,
Chemotherapy
1. Introduction
Oral cancers are one of the most well described & clearly detailed cancers in
history, since the times of ancient Egyptian and Ayurveda (Sushrutha) systems.
Globally, as per the data released from International Agency for research on cancer
(IARC), oral cancer occurs most commonly in middle- & low-income countries
with worldwide incidence of 377,713 cases with 177,757 deaths seen in 2020. [1] The
worldwide incidence rate is 4.1 cases per 100,000.
Since the evolution of modern contemporary management for oral cavity
cancers, radiotherapy has played a pivotal role along with surgery and recently with
chemotherapy in improving patient outcomes. After the milestone discovery of
x-rays by Wilhem Roentgen in 1898, utility of radiation in various cancers was
established. The role of radiotherapy in oral cancers specifically, developed between
the two world wars, as the morbidity was less troublesome and was easier to deliver
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in community hospitals. [2] However, as surgical processes got more flexible and
easier to execute and the survival rates of patients receiving radiation alone were
not very encouraging, radical surgery resurfaced as the primary modality for oral
cancers mid-century. Also, concerns of long-term radiation morbidity affecting
patient’s quality of life, in those receiving conventional radiation as a sole modality
came to the fore. Keeping this in mind, towards the end of the 20th century,
development of newer technology was directed towards minimising these particular
issues. Also, optimum and effective combinations between surgery & radiotherapy
with or without the addition of chemotherapy, were slowly established as standards
of care which have been thoroughly reviewed in this chapter.
In order to keep the options simple and to make the life of an oncologist simpler,
one can divide oral cancers as early, locally advanced and metastatic disease. In this
chapter, we will give an overview of the current understanding for the choice of
treatment in these different categories with insight into the specific therapeutic
aspects of both external & internal radiation therapy. We will also dwell upon the
advances in recent research related to oral cancer management as well as the
possible future directions from the prism of the new age radiation oncologist.
2. Basic aspects in oral cavity cancers
2.1 Anatomy from an oncologist perspective
In order to understand a disease, one needs to be well versed with the anatomy
of the area and since we want to know the way this would influence a radiation
oncologist’s outlook, the following section will address anatomy from a radiation
oncologists’ perspective (Figure 1).
Oral cavity includes lips, buccal mucosa, gingivobuccal sulcus, superior and
inferior alveolar ridges, teeth & mandible, oral tongue, floor of mouth (FOM),
Figure 1.
Anatomical aspects of oral cavity.
2
Oral Cancer - Current Concepts and Future Perspectives
retromolar trigone (RMT) and hard palate. [3] One needs to know a few terminol-
ogies like buccal mucosa which means mucosal surface of lips and cheek, whereas
gingival mucosa means mucosal lining of teeth, alveolar arches and gums. The area
of maximum incidence of squamous cell carcinoma is at the gingivobuccal sulcus
which is the junction of buccal mucosa to gingival mucosa. Floor of mouth is the
U-shaped sling formed due to joining of two mylohyoid muscles to a fibrous median
raphe. Oral tongue also known as Anterior 2/3rd of tongue includes the tip, lateral
border and body which consists of intrinsic and extrinsic muscles. It is imperative to
know the muscles as their involvement can upstage the disease, which will be
discussed later in the chapter. Intrinsic muscles have no bony attachment and are
divided into longitudinal, transverse and vertical groups. Extrinsic muscles do have
a bony attachment and originate outside the tongue, and are made up of four paired
bundles - genioglossus, hyoglossus, styloglossus and palatoglossus. These can be
appreciated well on a CT scan and an MRI scans.
The most important feature of neoplasia is the potential for spread and the most
common route of spread in oral cavity tumours is the lymphatic spread (Figure 2).
Since radiotherapy is a branch which tackles locoregional disease it becomes imper-
ative to have a thorough knowledge of the lymphatic drainage. In order to under-
stand this better, we are dividing the lymphatic channels as functional pathways:
1.Main lymphatic pathway: submental ➔ submandibular ➔ anterior
jugulodigastric ➔ middle and lower deep cervical nodal groups ➔ jugular
collecting trunk
2.Posterior accessory pathway: posterior part of jugulodigastric group ➔
middle and deep posterior cervical groups
3.Anterior lymphatic pathway: submental and jugulo-omohyoid ➔ lower
internal jugular nodes.
4.Superficial lateral pathway: occipital and mastoid group.
Figure 2.
Description of various nodal levels in the neck.
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2.2 Basic principles of treatment and broad guidelines
Radiotherapy is loco-regional form of treatment just like surgery. In oral cavity
cancers one needs to keep in mind the functionality and cosmesis when deciding on
the management, hence it requires a multidisciplinary team to take a call. For
management and prognosis reasons, these tumours are divided in to early stage,
locally advanced and metastatic tumours. The flow chart provides concise & defin-
itive steps on how to manage oral cavity tumours. (Figure 3).
For any malignancy there are only three weapons and they are surgery, radiation
therapy and systemic therapy. The sequencing and need of each therapy are a point
of debate. However, in oral cavity tumours, mostly all modalities are required and
sequencing is usually pre-determined and rationale is also established.
2.2.1 Early stage
As per TNM this group includes cT1 and cT2, which means localised tumours
only. This group is usually tackled by surgery or radiation therapy and role of
systemic therapy is limited (Table 1).
Figure 3.
Overview of management of Oral cancers.
Surgery Radiation therapy Rationale
Lip Yes Yes Cosmetically better
Buccal mucosa Yes Yes If localised and margins are clear
Tongue Yes No Usually aggressive and depth can be better made out
on hpe than mri
FOM No Yes As organ preservation is better
RMT No Yes As posterior margin will not be an issue
Table 1.
Rationale for application of radiotherapy in early oral cancers.
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2.2.2 Locally advanced disease
As per TNM this group will include cT1-4 and N+ disease. Basically, it means
that the disease has spread to nodes and or direct extension to surrounding struc-
tures. This group has to be addressed by combined modality therapy and there will
always be some amount of deliberation to be had about the sequencing of the three
modalities (Table 2).
Recurrent tumours: a tumour can be suggested to have recurred if there is
disease recurrence after a period of documented complete remission and usually it
is taken as 2 follow-ups of 6 weeks apart with a period of 6 months post primary
therapy. Based on this they can be:
1.Locally recurrent: the plan of treatment will depend on the primary therapy
received and also the operability. Usually, it is important to reassess the disease
to take a call on treatment. If the disease is operable, salvage surgery gives best
results. If more than 2 years has elapsed post primary therapy, then radiation
can also be advised based on site of recurrence.
2.Locoregionally recurrent: if the duration post primary therapy is more than
2 years and if operable then both salvage surgery with radiation can be offered
or else based on the status the treatment can be tailored.
3.Metastatic: these are usually managed with palliative systemic therapy and role
of radiation is limited to palliation to relieve the symptoms such as bleeding,
pain or dysphagia.
In the following section we are going to address the basis of radiation, how it is
delivered and what are the relevant toxicities encountered.
2.3 Basis for radiation
2.3.1 What is radiation?
One needs to remember that discovery of many great things happened by acci-
dent. Same thing holds good for practice of radiotherapy, as its use was established
when Henry Becquerel left 200 mg of Radium in his vest pocket for 6 hours and




LIP Surgery followed by Radiation +/
Chemotherapy
As locally advanced one modality will not be
able to achieve cure.
BUCCAL
MUCOSA
Surgery followed by Radiation +/
Chemotherapy
Locally advanced diseases tend to recur locally
TONGUE Surgery followed by Radiation +/
Chemotherapy
Usually aggressive and tend to recur locally as
well as systemically
FOM Radiation and chemotherapy As organ preservation is better
RMT Radiation and chemotherapy As posterior margin will not be an issue
Table 2.
Rationale for combined modality therapy in advanced oral cancers.
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scientific community towards the clinical effects of radiation & radioactive sources.
From then on, there were many experiments done to establish the role of radiation
in treatment of malignancy.
Radiation is nothing but energy in the form of waves or stream of particles
which can be explained by emission, propagation and absorption of energy. In the
present day, most common form of radiation in use is X-rays though there are
utilisation of gamma in brachytherapy and proton in particle therapy but in order to
restrict ourselves to common terminologies we are not going in detail about them.
This form of radiation is considered to have the ability to produce ions in the cells of
tissues it passes through, by dislodging the electrons from atoms, and hence it is
commonly called as ionising radiation.
If one needed to know the most basic principle about radiation, it would be that -
“radiation is effective only on dividing cells”. There are 5 phases that each cell goes
through from G0 ➔ G1 ➔ S ➔ G2 ➔ M. Among these G2 & M phases are the
most radiosensitive and S phase is the most radioresistant phase. The knowledge of
these help in deciding on combination therapy and use of radiosensitisers. Radiation
is usually delivered in a fractionated manner and it would be paramount to have
the knowledge of the 4R’s of radiation therapy to understand the basis for this
fractionation:
• Repair: differential rate of repair between tumour & normal tissue cells, is
what is utilised in fractionation
• Repopulation: this helps in normal tissues such that if one cell dies, then due to
compensatory mechanisms other cells divide rapidly to replace this loss.
• Reoxygenation: oxygen is the most important component for both cell survival
and also for effective action of radiation.
• Redistribution: as cell death happens there will be redistribution, making the
cells in less radiosensitive phases to move to more radiosensitive phases, thus
making radiation very effective and forms another basis for fractionation.
2.3.2 How is it delivered?
One can divide this based on technology, based on setting and based on type.
The following flowchart will briefly describe about it. (Figure 4).
Description of these commonly employed terminology are as follows
Figure 4.
Aspects of radiotherapy in Oral cancers.
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1.External radiation: radiation delivered from a distance away from the body is
called external radiation and the unit that’s commonly employed for this are
known as linear accelerators. There are different types of radiation that are
used such as X-rays, gamma rays and particle therapy like protons.
2.Brachytherapy: delivery of radiation in close proximity to or within the target
tissue is known as brachytherapy. The usual sources used are Iridium192 and
Cobalt60.
3.Conventional: it is the traditional way of radiation delivery, where the dose is
delivered without much conformity and is based mainly on bony landmarks.
4.Conformal: it is a contemporary form of radiation delivery where in the
conformity is good and avoidance of normal structures can be achieved.
5.Definitive: it means radiation is the main modality of treatment and it is used
with an intent to cure.
6.Adjuvant: it means radiation is delivered post-surgery in order to mop up the
most probable microscopic disease that is present.
7.Palliative: as the name indicates is to only tackle the symptoms and give relief.
3. Evidence based review on current management concepts in oral
cavity cancers
3.1 Risk factors for locoregional recurrence
3.1.1 Risk factors which have been utilised traditionally
Oral cavity cancers are commonly managed with single modality treatment in
early stages and a combined modality approach in advanced stages. Radical,
oncologically-sound surgical approaches form the backbone of early cancers with a
meticulous assessment of the histopathological specimen. Even with appropriate
excisions, local and regional recurrences are an extremely concerning aspect which
can alter the eventual outcomes in these cancers.
Many retrospective studies and single institution prospective trials demon-
strated the benefit of adding radiation adjuvantly for oral cancer patients who have
undergone radical surgery. Cooper et al. collated data from RTOG #85-03 & #88-24
to retrospectively sort into 3 risk groups of presumed progressive risk to enable
adjuvant treatment decisions. [4] Group I included fewer than 2 involved nodes, no
ECE & negative surgical margins. Group II included at least 2 involved nodes or
presence of ECE of tumour with uninvolved margins. Group III included micro-
scopically involved surgical margins. Accordingly, comparing outcomes in groups I
to III, the loco-regional recurrence rates at 5 years was 17%, 27% & 61% and median
survival was 5.6 yrs., 2.6 yrs. and 1.5 yrs. respectively.
Langendijk et al. used the Classification and Regression Tree(CART) or the
Recursive Partitioning Analysis(RPA) method to construct homogenous subgroups
of well-known prognostication parameters to be able to identify locoregional recur-
rence risk. [5] Accordingly, 801 patients were divided into RPA 1 group(Interme-
diate risk) which included no ECE and free surgical margins; RPA 2(High Risk)
which included T1,T2 and T4 tumours with close or positive surgical margins or one
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positive node with ECE and RPA 3 (Very High Risk) which included T3 tumours
with close or positive margin, N3 neck or multiple nodes with ECE. The 5-year LRC
was 92%, 78% and 58% and OS rates were 67%, 50% and 36% for the three RPA
classes respectively.
Salama JK et al. used pooled multivariate analysis to give a consensus statement
on use of adjuvant therapy in head and neck cancers. [6] They divided patients into
two groups to identify their risk for developing loco-regional recurrences based on
pathological features. High risk group included those with involved surgical mar-
gins and extranodal spread. Low risk group included other adverse features such as
T3/4 tumours, perineural invasion, lymphovascular space invasion, multiple nodal
involvement and lower neck adenopathy. They advised for postop radiotherapy
alone for patients with low-risk features and addition of concurrent chemotherapy
for those with high-risk features. They also suggested postop radiotherapy dose of
upto 63Gy for high-risk features and 57Gy for those with low-risk disease.
Perineural Invasion (PNI): There is no standardised definition of this entity, but
the most accepted one is when tumour cells are present in any one of the three
layers of the nerve sheath & when tumour cells are in close proximity to the nerve
& involves more than one-third of circumference. Bur et al. identified an incidence
of PNI in literature of between 3 and 52%. [7] Though many authors have not been
able to assign prognostic significance to presence of PNI, some features such as
multiple foci of PNI, involvement of large nerves(>1 mm) and higher maximum
extent of PNI were associated with increased local failure and reduced disease
specific survival.
In the systematic review collated data from 13 retrospective studies, they iden-
tified local recurrence rates of 4.4% - 22.9%, regional recurrence rates of 12.3% -
30.8% and 5-yr overall survival estimates of 48–89.6% in those patients with pres-
ence of PNI. [7] In two studies from this review, where neck dissection was
conducted, regional failure rates were 12.3% and 17.6% which undermines the fact
of ineffective salvage options after this. However, the authors suggest that in the
absence of any prospective trial to assess the impact of PNI on loco-regional recur-
rence or survival, it would be imperative to discuss the options of treatment in
detail in those patients where positive PNI is the only risk factor post radical
surgery.
Depth of Invasion (DOI): Tumour thickness or depth of invasion has been
consistently identified as a predictor for cervical lymph node metastasis in oral
cavity cancers. Oral cavity cancers have occult nodal metastases of up to 40% in
clinically negative neck, which is usually managed with elective nodal dissection as
opposed to just observation. Huang et al. in their meta-analysis, have tried to
address this aspect and have concluded that the optimal cut-off point for DOI is
4 mm, to consider for neck management. [8]
In another study, Liao et al. followed-up patients who underwent surgery of
early-stage oral cavity cancers(pT1-2 N0) to identify poor prognostic features and
suggest for adjuvant therapy. [9] They found that poorly differentiated tumours
and DOI of 4 mm and above were both independent poor prognostic factors, and
when present together accounts for 2-yr regional failure of 42%. Hence, they sug-
gest for the use of PORT in this subset of early OC cancers.
Bulbul et al. conducted a meta-analysis of 8 studies (1427 patients), which used
frozen section (FS) evaluation to define margin status in early(T1/2N0) oral cavity
cancers. [10] They compared positive/close FS margins which was cleared by fur-
ther resection (R1 – R0), positive margin not cleared (R1) to those with negative
margins upfront (R0). They found that patient with R1-R0 had poorer local recur-
rence free survival (LRFS) when compared to R0, regardless of clearance which was
statistically significant. Furthermore, R1-R0 patients showed almost equal LRFS to
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that of R1, though the trend to worse result was with R1 patients. They concluded
that upfront positive/close margin was a marker of a locally aggressive disease
regardless of re-resection & correction. They also indicated that there should be
standardisation of the FS sampling method too.
3.2 Surgery followed by radiotherapy
The value of postoperative radiotherapy (PORT) for advanced head & neck
cancers, was established in 1970’s with few well researched studies. [11] Marcus
et al. suggested doses for OC cancers of 6500Rads to achieve high local control and
up to 7000rads for those with positive surgical margins. [12]
Outcomes in locally advanced cancers are suboptimal with primary failure being
loco-regional relapses. Hence combined modality treatments have been employed
to counter this aspect as well as to ascertain if they added to overall survival patterns
too. Lavaf et al. retrospectively analysed data from the Surveillance Epidemiology
End Results (SEER) data base to collate results on 8795 lymph node positive cases
of advanced head and neck cancers. [13] They found addition of adjuvant
radiotherapy in these patients improved 5 yr. overall survival rates (43.2% vs.
33.4%; p<0.001) and cause specific survival rates (50.9% vs. 42.1%).
Kao et al. did a similar SEER group analysis of advanced cancers of head and
neck region and specifically tried to address benefit of RT with respect to various
nodal stages and specific sites of disease. [14] Subset analysis found that all nodal
stages, including N1 Disease, has improved survival with the addition of adjuvant
RT. Also, in multivariate analysis, addition of RT in node positive oral cavity
tumours improved overall survival [HR, 0.84; 95% CI, 0.73–0.98; p = 0.025],
though it was not as significant as compared to the other head and neck sites.
Another population-based study done by Shrimeet al, tried to specifically
address the benefit of PORT in early-stage primary oral cavity cancers(pT1/T2N1)
with single ipsilateral node without extracapsular spread and being <3 cm in size.
[15] For all patients, adjuvant RT was associated with superior 5 yr. overall survival
[52.4% vs. 41.4%(p< .001)]. Survival advantage was statistically significant in T2
cases, with a trend to significance in T1 cases. When individual sub-sites were
analysed, PORT significantly improved survival in patients with cancers of oral
tongue [52.3% vs. 37.9%(p=.002)] and floor of mouth [39.9% vs. 17.7%(p=.003)].
Addition of Chemotherapy to Radiation in post-op setting: Several retrospective
and small prospective trials had showed improvement in outcomes of advanced
head and neck cancers by adding chemotherapy (adjuvant or concurrent) to post-
operative radiotherapy, especially in those with high-risk features such as inade-
quate margins, presence of extracapsular nodal spread and multiple involved nodes.
Single institution trials by Bachaud and Smid, revealed improved loco-regional
control rates and superior DFS/OS rates in combined modality group at a slightly
higher rate of complications. [16, 17]
Lacas & Pignon et al. (MACH-NC) in their updated meta-analysis of chemo-
therapy in head and neck cancer have studied the effect of concurrent chemother-
apy use along with radiotherapy (upfront & post-surgery). [18] Out of 107 studies
(19,805 patients), 71 studies (10,680 patients) were on concomitant chemotherapy
with a median follow up of 9.2 years. There was an absolute benefit in overall
survival & event free survival of 6.5% & 5.8% at 5 years and 3.6% & 3.1% at
10 years with significant reduction in LRF rates [sub-HR = 0.71; p < 0.0001]. The
study also showed that concurrent chemotherapy outcomes were better than
induction chemotherapy and also that platin based chemotherapy gave maximum
benefit, however there was no significant difference between weekly or
three-weekly chemotherapy protocols in terms of outcomes or toxicity.
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Bernier et al. (EORTC 22931) conducted a multi-institutional prospective study
in 334 patients and found that addition of chemotherapy to adjuvant radiotherapy
showed a benefit in 5 yr. PFS rates [47%(CMT) vs. 36%(RT)] and OS rates [53%
(CMT) vs. 40%(RT)] & reduced the 5-year risk of death in combined modality
from 43–27%. [19] Cooper et al.(RTOG 9501) did a similar study in 459 patients and
showed significantly improved local/regional control as well as disease free survival
(10% absolute benefit at 2 years) in the combined modality group after 45.9 months
follow up. [20]
As both these studies had few differences in their definition of high-risk disease,
a pooled analysis was done to get some clarity and this concluded that outcomes for
patients with ECE and/or involved surgical margins was significantly better with
CMT. [21] Also, there was a trend to improved outcomes in patients with clinically
enlarged level IV/V nodes with oral cavity/oropharyngeal primaries and perineural
infiltration.
Three weekly high dose cisplatin (100 mg/m2) is the standard systemic chemo-
therapy regimen given concurrently with radiation in high-risk oral cavity cancers.
However, due to compliance issues low dose regimens have been applied in clinical
practice without any prospective evidence to support the same. Szturz et al.
conducted a meta-analysis to compare the standard three weekly regimen (100 mg/
m2; 3 doses) with the low dose weekly regimen ≤50 mg/m2; ≥6 doses). [22] Though
there were no prospective comparative studies till date, 52 studies with 4209
patients were included and it showed no difference in the efficacy indices such as
overall survival or response rates. In the definitive treatment setting, weekly regi-
men was more compliant and significantly less toxic with respect to myelosup-
pression, severe nausea/vomiting and nephrotoxicity. In the post-op setting, the
two approaches were similar with the weekly arm causing more grade 3/4
dysphagia and weight loss.
JCOG1008 was a multi-institutional phase II/III non-inferiority trial
comparing 3 weekly cisplatin with weekly schedule (40 mg/m2) as a concurrent
chemotherapy option in post-operative high-risk H&N cancers. [23] After
enrolling 261 patients and a median follow up of 2.2 years, the trial was stopped as
the non-inferiority criteria was reached. The 3-year OS (76.1% vs. 59.1%; HR of
0.69) &RFS (64.5% vs. 53%; HR of 0.71) was favouring the weekly arm as
against the 3 weekly arm, confirming the non-inferiority of the lower dose weekly
regimen.
3.3 Definitive radiotherapy (with or without chemotherapy)
There are no prospective trials which have directly compared primary surgery
vs. primary radiotherapy in oral cavity cancers specifically. Two case series com-
paring these two modalities suggested a lower loco-regional control with primary
radiotherapy compared to a surgical approach.
First was Studer et al., who assessed 58 consecutive oral cancer patients referred
for either adjuvant or definitive radiotherapy. [24] They found local control rates
were highest in the surgery followed by post-op IMRT group (92% LC at 2 yr),
followed by patients treated with surgery alone or those receiving post-op 3DCRT
(70–80% LC at 2 yr) and least in the definitive radiotherapy group treated with
IMRT (40%LC at 2 yr) or 3DCRT (30% LC at 2 yr).
Murthy V. et al. studied 1180 oral cancer patients treated with PORT or defini-
tive RT, by dividing them into 2 groups – Group 1 included gingiva-alveolar-buccal
complex, lip and hard palate sites and group 2 included tongue and floor of mouth
sites. [25] The 3 yr. LC, LRC and DFS for those treated with PORT was 74%, 65% %
60% respectively. And for those treated with definitive RT it was 34%, 31% & 30%
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respectively. Also, they found Group 1 patients had significantly better LC, LRC
and DFS than group 2 patients.
Cohen et al. did a retrospective review of 4 multi-institutional phase II trials
dealing with primary chemo-radiotherapy for T4 oral cavity tumours. [26] In all 39
patients were assessed, 42% of them having bone involvement. Median dose of RT
given was 74Gy. Five-year OS, PFS and LC were 56%, 51% & 75% respectively
suggesting definitive chemoradiation to be a reasonable option in these tumours.
Hosni et al. retrospectively analysed all oral cancer patients (108 patients)
treated with IMRT (with no surgical intervention). [27] The cases had 63% cT3/T4
disease, 35% cN2/3 and 35% received concurrent chemotherapy. After a median
follow up of 52 months, the 5-year local, regional and distant control rate was 78%,
92% & 90% respectively. The 5-year DFS, OS and CSS were 42%, 50% & 76%
respectively justifying definitive non-surgical chemoradiation as a meaningful
alternative in appropriately chosen cases.
Updated MACH-NC results showed the benefit of concomitant chemotherapy
was due to its effect on deaths related to head and neck cancer (absolute benefit of
9.8% in 5 years). [18] Addition of chemotherapy showed a significant reduction in
loco-regional failure (sub-HR = 0.71; p<0.0001) with a non-significant effect on
distant failure.
The first Meta-Analysis of Radiotherapy in Head and neck cancer (MARCH) in
2005 and clearly showed an advantage of altered fractionation radiotherapy over
conventional radiotherapy in terms of overall and progression free survival. The
updated analysis of this study was conducted by Lacas et al. in 2017 by including
34 trials and 11,969 patients and extended the comparison to benefit of concomitant
chemoradiotherapy over altered fractionation schemes. [28] They reiterated that
altered fractionation was superior to conventional RT alone schemes in all
disease indices and also that hyperfractionation schemes were better than
accelerated RT plans especially when nodal disease was higher. The comparison
between concomitant chemoradiation and altered fractionation revealed a clear
benefit for CMT with an absolute benefit of 5.8% and 5.1% at 5 & 10 years
respectively.
Combining altered fractionation RT schemes with chemotherapy in head and
neck cancers have been studied in the following two trials. GORTEC 99–02 did a
three-arm study comparing standard chemoradiation, accelerated radiotherapy-
chemotherapy and very accelerated radiotherapy alone. [29] Progression free sur-
vival were 37.6%, 34.1% & 32.2% respectively with acute grade 3/4 toxicity of 76–
84% in the altered fractionation arms. The RTOG 0129 trial did a direct head on
comparison between standard fractionation chemoradiotherapy and accelerated
chemotherapy-radiotherapy in 743 patients. [30] At a median follow up of
7.9 years, there were no differences in OS, PFS, LRF or DM rates between the two
arms. Both these studies concluded that addition of chemotherapy to altered frac-
tionation radiation schemes in locally advanced head and neck cancers provided no
benefit in terms of outcomes.
3.4 Time factor in PORT
Two aspects of timing with regards to radiotherapy has been shown to be
important for eventual outcomes in head and neck cancer management – overall
treatment duration of radiotherapy as well as total time of both surgery and radio-
therapy in CMT. Prolongation of both these indices seems to negatively impact the
outcomes. Ang et al. conducted a multi-institutional study including 288 patients
and found that in high-risk H&N cancers, there was a trend towards higher LRC
and survival rates when PORT was delivered in 5 rather than 7 weeks. [31] Also, a
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prolonged interval between surgery and PORT of >6 weeks or a total duration of
surgery and PORT of >13 weeks significantly impacted outcomes negatively.
Huang et al. in their meta-analysis involving 46 studies dealing with this aspect
found that in the combined analysis the rates of local recurrences were significantly
higher among patients who received PORT more than 6 weeks after surgery (OR =
2.89; 95% CI). [32]
Fast tumour cell repopulation has been postulated as the reason behind why
prolonging overall treatment time (OTT) can negatively impact local control and
survival in cancers. González Ferreira et al. in their review of literature found
prolongation of OTT resulted in an average loss of LRC ranging from 1 to 1.2%per
day to 12–14% per day, requiring an average increase of 0.6–0.8Gy/day to compen-
sate for it. [33] Also, they postulated that the lag period for the accelerated
repopulation to be initiated was between 21 and 28 days.
Graboyes et al. conducted an institutional review to study this aspect and found
that starting PORT > 6 weeks post-surgery resulted in decreased OS rates in both
multivariate and propensity score-matched subsets. [34] They also found that
increasing delay beyond 6 weeks resulted in small, progressive survival decrements
[aHR 1.09, 1.10, 1.12 for 7–8 wks, 8–10 wks and >10wks respectively].
Zumer et al. did a retrospective analysis to identify the relationship between
time before treatment intervention and tumour growth kinetics on treatment out-
comes in those undergoing definitive radiotherapy with or without chemotherapy
in 273 head and neck cancer patients. [35] There was no significant association
between loco-regional control or survival indices and time to treatment interven-
tion. They also found that the median tumour volume relative increase rate &
tumour volume doubling time was 3.2%/day and 19 days respectively, but both had
no impact on outcomes.
3.5 Dose & volumes considerations for radiation in oral cancers
As a principle in radiotherapy, at least for oral cavity squamous cell carcinomas,
the dose needs to be delivered in the desired fractionated regimen without unnec-
essary interruptions and in the shortest time possible with no reduction in dose
below that what is tolerated by late responding normal tissue.
This means that the total dose is important to prevent local recurrences and the
factors that need to be kept in mind are [36].
• Dose
• Dose per fraction
• Overall treatment time
• Normal tissue toxicity
Radiotherapy in oral cavity tumours is associated with lot of acute as well as
chronic toxicities which will be dealt separately. In order to minimise this, there are
several steps taken and one of them is the use of highly conformal Intensity modu-
lated radiotherapy (IMRT), and there is lot of data to support its use in head and
neck cancers. Before starting radiation therapy all patients undergo a detailed
examination by a dental surgeon and this is known as dental prophylaxis. The
dental surgeon will assess the area of treatment and also estimate the dose that
would probably be delivered to the surrounding bony structures as well as ascertain
the status of the teeth and score it as per DMF (Decayed, Missing, Filled) index.
12
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Based on this, treatment is advised and appropriately followed. By doing this exer-
cise, the chances of osteoradionecrosis & soft tissue related long-term toxicities can
be reduced or even eliminated. IMRT involves simulation and planning for which
the most basic step is immobilisation by thermoplastic facemask attached to a base
plate indexed to the treatment table. After the planning CT scan is done the volumes
are outlined on them as per the guidelines. [37]
3.5.1 For definitive radiation therapy
GTV or gross tumour volume is defined as the visible tumour along with the
nodes which are abnormal. HRCTV [High Risk Clinical Target Volume] includes
the margin around the GTV and also the first echelon group of nodes which will be
level IB to level II. For LRCTV [Low Risk Clinical Target Volume] one would
include level III, IV, supraclavicular and IA. Usually bilateral neck is to be treated,
based on institutional protocol. PTV [Planning Target Volume] would be 5 mm
around the CTV trimmed from skin, but based on institutional protocol, it could
range from 3 mm to 10 mm. (Figures 5 and 6).
3.5.2 For postop radiation therapy
HRCTV encompasses the area of the tumour bed [if features such as margin
positivity, node positivity with extracapsular extension, peri-neural invasion and
soft tissue extension is present]. IRCTV [Intermediate Risk Clinical Target Volume]
would include the involved nodes without ECE & uninvolved adjacent nodal levels.
Figure 5.
Contouring of target volumes & organs at risk(OAR) for a case of carcinoma Oral tongue post surgery
[pT3N1M0]; Orange – clinical target volume; Red – planning target volume; Cyan – mandible; brown – right
parotid; green – spinal cord; pink - constrictor.
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LRCTV would include rest of the nodal levels based on the risk stratification and
bilateral neck is treated if risk is higher. PTV would be 5 mm around the CTV
trimmed from skin, but based on institutional protocol, it could range from 3 mm to
10 mm. (Figure 5).
As far as dose and dose per fraction is concerned there are multiple regimens and
multiple doses available with their pros and cons. The following table depicts the
usual practice with some insight on hypothesis. (Tables 3 and 4).
3.6 Radiation related toxicity in oral cancer management
Radiotherapy is an essential part of multi-modality treatment for oral cancers.
However, several uninvolved organs in the vicinity of these cancers like the skin,
salivary glands, oral mucosa, masticatory apparatus, dentition and jaws receive
significant doses of radiation during treatment. This could result in moderate to
severe adverse effects during and after completion of treatment and also affect the
patient’s quality of life. The effects may be acute such as dermatitis, mucositis
and hyposalivation or chronic and long-term such as xerostomia, radiation caries,
trismus and osteoradionecrosis. [38]
As many of these effects are dose-limiting, introduction of newer radiation
techniques and schedules have minimised late effects to a large extent. Nutting et al.
were able to demonstrate 50% reduction in subjective xerostomia rates with IMRT
by keeping mean dose to contralateral parotid gland at 26Gy. [39] Parotid sparing
IMRT was achieved by avoiding the contralateral parotid, upper parapharyngeal
space as well as giving a tight constraint for the anterior oral cavity. [36, 40]
A more problematic late effect is osteoradionecrosis, which is the process of
bone and soft tissue necrosis, arising as a result of radiation induced hypocellularity,
hypoxia and hypovascularity, resulting in a non-healing region. [41] As spontane-
ous ORN is dose dependent(>60Gy), IMRT is able to reduce the maximum
Figure 6.
3-dimensional projection of target & normal tissues contoured.
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Post operative disease
R1-Microscopic Disease R0 Resection R0 & N0 Disease
NODE +, ECE/PNI + NODE +, No ECE/PNI ELECTIVE ONLY
RISK OF RELAPSE –
>30%
RISK OF RELAPSE –
15–20%










66Gy–70Gy at 2Gy per
fraction
DOSE –
60Gy at 2Gy per fraction
DOSE –
50Gy at 2Gy per
fraction
Table 3.


















66Gy–70Gy at 2Gy per
fraction
DOSE –
60Gy at 2Gy per
fraction
DOSE –
50Gy at 2Gy per fraction
Table 4.
Dose & volume consideration for definitive radiotherapy.
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dose received by the mandible as well as volume of mandible covered by 50-55Gy
isodoses. The reported ORN rates in IMRT series is 5–6%.
Chen et al. found that IMRT also helped reduce dysphagia related complications
in oral cancer patients undergoing radiotherapy. [42] Those receiving IMRT had
significantly lesser moderate (grade 2) and severe(grade 3) dysphagia when com-
pared to those receiving conventional radiotherapy (21% vs. 59%; p = 0.02) [42]
3.7 Targeted therapy, current bio-markers and future perspectives for oral
cancers
Epidermal growth factor receptor (EGFR) regulates many cellular functions
crucial for tumorigenesis. Huang et al. studied 160 oral cancer patients using
immunohistochemistry for EGFR protein over-expression and fluorescence in situ
hybridization for copy number. [43] EGFR overexpression was noted in 46.88%
and 31.25% had increased gene copy numbers. They also found 100% concordance
rate between EGFR gene amplification and protein overexpression. EGFR over-
expression was associated with poor prognosis, both in terms of DFS and OS.
Cetuximab, an EGFR antibody has shown good results in head and neck cancers,
in combination with definitive radiation. [44] The RTOG 0920 trial (Ongoing) is
trying to address outcomes with addition of cetuximab to PORT in intermediate-
risk oral cancers.
The development of PD-1/PD-L1 inhibitors (pembrolizumab & nivolumab) &
other immune checkpoint inhibitors (ICI) has changed the systemic management of
HNSCC. [45, 46] PD-L1 expression in pre-treatment biopsies have been associated
with good prognosis. Preclinical data suggests synergy between anti-PD1 inhibitors
and radiation, making it a potential therapeutic option for high-risk oral cancers in
the future. [47] Several phase II studies addressing these agents in combination with
standard therapy or as a neoadjuvant/adjuvant option are in the works. [48]
Tumour mutational burden (TMB) as a biomarker of ICI response has shown
mixed response in HNSCC, with KEYNOTE-012 trial showing a positive correlation
while using a cut-off of ≥102 mutations per exome. [49]
Other aspects being studied are tumour immune microenvironment and oral/gut
microbiome as regulating mechanisms having implications for response of HNSCC
to immune therapies. Oral microbiome has also shown an effect on toxicity profile
of patients undergoing concurrent chemoradiation. [50] Cell therapy-based options
such as the use of activated cytotoxic T-Lymphocytes (CTL’s) to result in tumour
cell death has also been attempted in HNSCC. [51] Chimeric antigen Receptor T
cells are one such example being used in advanced oral cancers.
4. Brachytherapy
Brachytherapy is the delivery of radiation therapy using sealed sources placed
within or close to the site to be treated. Oral cavity cancers with their ease of
accessibility and better visibility had provided the best sites for use of this therapy
for improved local control and outcomes in the past. With its ability to give high
doses to tumour and very minimal dose to the surrounding tissues, brachytherapy
could be considered the most ideal conformal therapy. However, in recent times the
technological advancements associated with external beam therapy, improved
imaging and surgical techniques and lack of appropriate knowledge or expertise in
invasive implants has relegated brachytherapy to be used in very specific and not so
common indications of these cancers. Modern brachytherapy too has evolved to
16
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allow for acceptable dose and fractionation schedules, image guidance, dose opti-
mization and better radiation protection mechanisms.
Common cancer sites where brachytherapy can be used in oral cavity are mobile
tongue, lip, buccal mucosa, floor of mouth and palate. [52, 53] Indications for use of
brachytherapy presently is
• Small localised T1 squamous cell cancers as primary treatment
• In combination of external beam radiotherapy as a boost modality
• As a re-irradiation modality in previously treated sites or development of
second primaries
Disadvantages for brachytherapy are primarily due to lack of expertise and need
for an initial learning curve which is usually lacking other than in bigger institutes,
ease of modern conformal external radiotherapy techniques, competition with
modern surgical techniques and concerns of radiation protection. Some relative
contraindications to this procedure in oral cavity tumours would be compromised
mouth opening, difficult naso-tracheal intubation & those having large defects
requiring flap reconstructions in post-op setting.
Usually, the procedure followed is a single implant with multiple treatment
fractions over nearly a week. Procedure is done under general anaesthesia with the
help of nasotracheal intubation and dental separators to allow for proper visualisa-
tion. An interstitial implant is done following the principles of the Paris technique.
(Figures 7 and 8) A CT-scan based planning is done and the oncologist will delin-
eate the tumour and organs at risk on the treatment planning system. Doses deliv-
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the primary treatment setting and 3-4Gy in 6–8 fractions over 3–4 days in the boost
setting.
Acute complications of brachytherapy could be haemorrhage, infection, airway
compromise & sialadenitis. Long term side effects could be soft tissue necrosis,
telangiectasia and rarely osteoradionecrosis.
5. Conclusions
Oral cavity cancers are a diverse group of tumours which are known for its
aggressive behaviour and higher chances of recurrences, which can lead to
extremely difficult & cumbersome management decisions. This current review
denotes the various available options for treatment for different categories of these
tumours, to provide us a glimmer of hope to not only manage the disease well but
also give good results in terms of locoregional control, long-term survival and at the
same time ensuring cosmetically acceptable outcomes. As the primary focus of this
chapter was on aspects of use of radiotherapy in oral cancers, the specific nuances
on current evidence-based practice have been elaborated upon. Though most of the
general details on use of external & internal radiation in oral cancers have been
described, the detailed specific site-based & technique-based points have not been
elaborated as they are beyond the scope of this chapter.
Available potential therapeutic options being currently investigated to ascertain
possible benefit in oral cancers have also been described in this chapter. The future
advances in use of radiation therapy should focus on recognising & refining the
most appropriate indications for its application, strategic use of higher end technol-
ogy like modulated arc therapy/stereotactic radiation & proton therapy, better
amalgamation of radiation with newer concomitant systemic therapy agents as well
as a well-rounded approach in inculcating genomic attributes of oral cancers in
identifying the future standard of care for these tumours.
Figure 8.
Brachytherapy of buccal mucosa.
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